SHANGHAI, Sept. 15, 2021 /PRNewswire/ -- Molecular Data
Inc. (Nasdaq: MKD), a leading technology-driven platform in
China's chemical industry, today
announced it has entered into definitive agreements with investors
for the purchase and sale pursuant to a registered direct offering
of (i) common units, consisting of one American Depositary Share,
or ADS, each representing three of its Class A ordinary shares, and
one warrant to purchase one ADS and (ii) pre-funded units,
consisting of one pre-funded warrant to purchase one ADS and one
warrant to purchase one ADS. The purchase
price of the common units was $0.38
per unit. The purchase price of the pre-funded units was
$0.3799 per unit. The exercise price
of the pre-funded warrants is $0.0001, and the exercise price of the ADS
warrants is $0.38. The gross
proceeds of the offering will be approximately $15 million, before deducting placement agent
fees and other estimated offering expenses. The Company intends to
use the net proceeds for working capital and for other general
corporate purposes. The closing of the registered direct offering
is expected to take place on or about September 17, 2021, subject to the satisfaction
of customary closing conditions.
Aegis Capital Corp. is acting as sole lead placement agent
for the offering.
This offering is being made pursuant to an effective shelf
registration statement on Form F-3 (File No. 333-256451) previously
filed with the U.S. Securities and Exchange Commission (the "SEC").
A prospectus supplement describing the terms of the proposed
offering will be filed with the SEC and will be available on the
SEC's website located at http://www.sec.gov. Electronic copies of
the final prospectus supplement and the accompanying prospectus may
be obtained, when available, by contacting Aegis Capital Corp.,
Attention: Syndicate Department, 810 7th Avenue, 18th floor,
New York, NY 10019, by email at
syndicate@aegiscap.com, or by telephone at (212) 813-1010. Before
investing in this Offering, interested parties should read in their
entirety the prospectus supplement and the accompanying prospectus
and the other documents that the Company has filed with the SEC
that are incorporated by reference in such prospectus supplement
and the accompanying prospectus, which provide more information
about the Company and the Offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Molecular Data Inc.
Molecular Data Inc. is a technology-driven platform in
China's chemical industry,
connecting participants along the chemical value chain through
integrated solutions. The Company delivers e-commerce solutions,
financial solutions, warehousing and logistics solutions, and SaaS
suite that are intended to solve pain points for participants in
the traditional chemical industry. Built upon a comprehensive
knowledge engine and artificial intelligence (AI) capabilities, the
Company's e-commerce solutions are mainly offered through its
online platform, consisting of molbase.com, molbase.cn, Moku Data
WeChat account, Chemical Community APP and other ancillary
platforms.
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
"will," "expects," "anticipates," "aims," "future," "intends,"
"plans," "believes," "estimates," "confident," "potential,"
"continue" or other similar expressions. Among other things, the
quotations from management in this announcement, as well as the
Company's strategic and operational plans, contain forward-looking
statements. The Company may also make written or oral
forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission, in its annual report to
shareholders, in press releases and other written materials and in
oral statements made by its officers, directors or employees to
third parties. Statements that are not historical facts, including
but not limited to statements about the Company's beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a variety
of factors could cause actual results to differ materially from
those contained in any forward-looking statement, including but not
limited to the following: the Company's goals and strategies; the
Company's future business development, results of operations and
financial condition; the expected growth of the chemical market;
the Company's ability to monetize the user base; fluctuations in
general economic and business conditions in China; the potential impact of the COVID-19 to
the Company's business operations and the economy in China and elsewhere generally; and assumptions
underlying or related to any of the foregoing. Further information
regarding these and other risks is included in the Company's
filings with the Securities and Exchange Commission. All
information provided in this press release is as of the date of the
press release, and the Company undertakes no duty to update such
information, except as required under applicable law.
View original
content:https://www.prnewswire.com/news-releases/molecular-data-inc-prices-15-million-registered-direct-offering-301377651.html
SOURCE Molecular Data Inc.